Literature DB >> 83812

Experimental allergic encephalomyelitis in cobra venom factor-treated and C4-deficient guinea pigs.

M A Morariu, A P Dalmasso.   

Abstract

Experimental allergic encephalomyelitis (EAE) was studied in guinea pigs with an inherited deficiency of the fourth component of complement (C4) and in guinea pigs injected with cobra venom factor to deplete the third component and late-acting components of complement. EAE was elicited by immunization with homologous spinal cord or purified basic protein. Administration of cobra factor after the injection of encephalitogenic emulsion delayed the onset and reduced the intensity of the clinical manifestations of EAE. In addition, cobra factor markedly reduced mortality during the sixty days of observation. However, pathological changes of perivascular infiltration and demyelination were similar in cobra factor-treated and untreated animals. Clinical signs of EAE an mortality in C4-deficient guinea pigs were no different from those in normocomplementemic controls. Thus, although activation of the classic complement pathway does not appear to be involved in the production of EAE in guinea pigs, our results suggest a possible role of the alternative complement pathway in the pathogenesis of EAE.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 83812     DOI: 10.1002/ana.410040507

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  7 in total

1.  Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation.

Authors:  S Piddlesden; H Lassmann; I Laffafian; B P Morgan; C Linington
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

2.  Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis.

Authors:  C Linington; H Lassmann; B P Morgan; D A Compston
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

3.  The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis.

Authors:  Qing Li; Kristine Nacion; Hong Bu; Feng Lin
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

4.  Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.

Authors:  Xianzhen Hu; Stephen Tomlinson; Scott R Barnum
Journal:  Neurosci Lett       Date:  2012-10-16       Impact factor: 3.046

Review 5.  The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.

Authors:  Jessy John Alexander; Aileen Judith Anderson; Scott Robert Barnum; Beth Stevens; Andrea Joan Tenner
Journal:  J Neurochem       Date:  2008-10-24       Impact factor: 5.372

Review 6.  Complement in multiple sclerosis: its role in disease and potential as a biomarker.

Authors:  G Ingram; S Hakobyan; N P Robertson; B P Morgan
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

Review 7.  Complement activation in the injured central nervous system: another dual-edged sword?

Authors:  Faith H Brennan; Aileen J Anderson; Stephen M Taylor; Trent M Woodruff; Marc J Ruitenberg
Journal:  J Neuroinflammation       Date:  2012-06-21       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.